26
total announcements
JAGSNPHARM.BO · 15 min delayed
Key Stats · Yahoo Finance · as of 21 Oct 2026
Market Cap
₹1,435 Cr
P/E (TTM)
32.4
EPS (TTM)
₹6.71
52W Low
₹154.90
52W High
₹264.65
Dividend Yield
1.15%
Beta
-0.27
Price / Book
5.5
Debt / Equity
3.0
Revenue (TTM)
₹294 Cr
Gross Margin
63.90%
Operating Margin
18.36%
Jagsonpal Pharmaceuticals Ltd
Jagsonpal Pharmaceuticals Ltd announced Q1 FY27 results with revenue up 9%, PAT up 22%, and cash reserves at ₹1,700 Mn. The company also completed the acquisition of a controlling stake in Aequitas Healthcare and concluded a ₹40 crore share buyback.
Jagsonpal Pharmaceuticals Ltd
Jagsonpal Pharmaceuticals Ltd has announced its Q1 FY27 results, with revenue up 9% YoY, PAT up 22% YoY, and cash reserves at ₹1,700 Mn. The company has also completed the acquisition of a controlling stake in Aequitas Healthcare and concluded a ₹40 crore share buyback.
Jagsonpal Pharmaceuticals Ltd
Jagsonpal Pharmaceuticals Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with the company's management and board of directors approving the results. The results are in compliance with Indian Accounting Standard 34 and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The auditor's review report has not identified any material misstatements in the financial results.
Jagsonpal Pharmaceuticals Ltd
Jagsonpal Pharmaceuticals Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with the Board of Directors approving the results at its meeting held on July 29, 2026. The results are in compliance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting.
Jagsonpal Pharmaceuticals Ltd
Jagsonpal Pharmaceuticals Ltd has scheduled a conference call with analysts/investors on July 30, 2026, to discuss its Q1 FY27 financial results.
Jagsonpal Pharmaceuticals Ltd
Jagsonpal Pharmaceuticals Ltd has scheduled a board meeting on July 29, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026, and has closed the trading window till July 31, 2026.